FDA gives a mixed response to a petition seeking greater clinical trial transparency; Novavax and Gavi end a bitter dispute over Covid-19 vaccines

Taking stock of the drug industry, from the lab to the medicine chest

February 22, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT+ | FDA gives a mixed response to a petition seeking greater clinical trial transparency The petition followed years of complaints that drug companies, universities, and academic medical centers fail to follow federal law. By Ed Silverman STAT+ | Novavax and Gavi end a bitter dispute over Covid-19 vaccines with a refund up to $475 million Initially, Gavi sought $700 million in payments that were made to Novavax for vaccines that were never delivered. By Ed Silverman Small study adds to growing hope CAR-T cell therapy could revolutionize autoimmune disease treatment A small study of lupus, scleroderma, and idiopathic inflammatory myositis found patients given CAR-T therapy had symptoms improve or go away. By Theresa Gaffney Roman Minchyn/Wikimedia Commons War zone or not, Ukraine seeks to reclaim its role as a hub for clinical trials Researchers and executives are increasingly urging companies to restart clinical trials, insisting that the war is an obstacle that can be surmounted. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser